This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| MCF-7 | |
|---|---|
| Name | MCF-7 |
| Species | Human |
| Tissue | Breast adenocarcinoma |
| Subtype | Luminal A |
| Morphology | Epithelial |
| Established | 1970 |
| Source | Pleural effusion |
| Institution | Michigan Cancer Foundation |
| Identifier | ATCC HTB-22 |
MCF-7 MCF-7 is a widely used human breast adenocarcinoma cell line originally isolated in 1970 and maintained as a model of estrogen receptor–positive breast cancer. It serves as a standard platform across laboratories in studies involving hormone response, chemotherapy screening, and tumor biology, and it appears in comparative studies alongside lines such as HeLa, MCF10A, T-47D, MDA-MB-231, and SK-BR-3. Laboratories at institutions like the National Institutes of Health, European Molecular Biology Laboratory, and Cold Spring Harbor Laboratory have contributed to its characterization and distribution.
MCF-7 was derived from a pleural effusion of a 69-year-old woman treated at the Michigan Cancer Foundation in 1970, at a time when cell culture advances from groups such as those at Roswell Park Comprehensive Cancer Center and Memorial Sloan Kettering Cancer Center were expanding cancer models. The line was distributed through repositories including the American Type Culture Collection and referenced in landmark studies published in journals associated with organizations like the American Association for Cancer Research and Nature Publishing Group. Early researchers compared MCF-7 to contemporaneous models such as HeLa and MCF10A to establish reproducibility and phenotype stability.
MCF-7 exhibits an epithelial morphology with polygonal cells forming cobblestone monolayers, similar to observations reported for lines like T-47D and ZR-75-1. It expresses markers including estrogen receptor alpha detected in studies involving investigators affiliated with Dana-Farber Cancer Institute and Johns Hopkins University. Under microscopy methods developed at The Rockefeller University and Cold Spring Harbor Laboratory, MCF-7 demonstrates cytokeratin patterns comparable to luminal breast tumors profiled by consortia such as The Cancer Genome Atlas and the International Cancer Genome Consortium.
The genomic landscape of MCF-7 includes copy number alterations, point mutations, and expression signatures that parallel luminal A tumors characterized in cohorts from The Cancer Genome Atlas and METABRIC. Key alterations reported in publications from groups at Sanger Institute and Broad Institute include variants affecting pathways studied by researchers at Harvard Medical School and Stanford University School of Medicine. Transcriptomic and proteomic datasets produced via platforms developed at Illumina, Thermo Fisher Scientific, and Agilent Technologies have been used to map signaling networks involving estrogen receptor signaling, PI3K/AKT pathways, and cell cycle regulators interrogated in collaborations with laboratories at Massachusetts Institute of Technology and Yale School of Medicine.
Standard culture of MCF-7 employs media formulations such as Dulbecco’s Modified Eagle Medium supplemented with fetal bovine serum sourced from vendors like Sigma-Aldrich, and handling protocols are informed by biosafety guidance from agencies including the Centers for Disease Control and Prevention and the World Health Organization. Passaging routines and mycoplasma monitoring adopted from workflows at European Molecular Biology Laboratory and American Type Culture Collection reduce contamination risk, while authentication practices using short tandem repeat profiling are recommended by repositories such as ATCC and initiatives led by International Cell Line Authentication Committee participants from institutions like University of Cambridge and University of Oxford.
MCF-7 is employed extensively in endocrine therapy research, drug screening, and mechanistic studies performed by teams at University of California, San Francisco, Vanderbilt University, and Scripps Research. It has been a benchmark in studies evaluating agents developed by pharmaceutical companies including Pfizer, Novartis, and AstraZeneca and in preclinical assays coordinated with consortia such as National Cancer Institute programs and collaborative networks like Cancer Research UK. Comparative work involving lines like MDA-MB-231 and BT-474 uses MCF-7 to dissect differences in invasion, metastasis, and receptor signaling described in reviews from journals affiliated with Wiley and Elsevier.
Critiques of MCF-7 include concerns about genetic drift, clonal heterogeneity, and representativeness relative to primary tumors highlighted in position statements from groups at European Society for Medical Oncology and meta-analyses by researchers at Karolinska Institutet and University College London. Cross-contamination incidents historically documented in literature involving HeLa underline the necessity of authentication emphasized by the International Cell Line Authentication Committee and regulatory bodies such as the Food and Drug Administration. Additionally, limitations in modeling tumor microenvironment interactions have prompted complementary use of organoid systems developed at Hubrecht Institute and patient-derived xenografts propagated at centers like Jackson Laboratory.
Multiple derivatives and sub-lines originating from MCF-7 have been generated, including hormone-resistant, drug-selected, and genetically modified variants produced in laboratories at Institut Curie, Weizmann Institute of Science, and Memorial Sloan Kettering Cancer Center. Sub-lines used in metastasis and resistance studies are often compared with engineered models from groups at Cold Spring Harbor Laboratory and Salk Institute, and many derivatives have been deposited with repositories such as ATCC and referenced in datasets curated by the European Bioinformatics Institute.
Category:Human cell lines